The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
WinnyFrith
How on earth do you link Avacta’s pre|Cision chemo product to COVID-19 vaccine rollouts. You really are a tw*t.
We remain on track to submit the UK regulatory application, or CTA, for AVA6000 pro-doxorubicin before the end of the year to allow first-in-human trials of the pre|CISIONTM chemotherapy platform at several clinical trial sites in the UK early in 2021.”
Ok so even the minimal amounts of jam expected will not arrive until the vaccines have been rolled out nationally. Great.
Reported
I whole-heartedly agree with this comment “So what if we don’t get a UK Govt contract? We’ll sell all we can make”
The BIG difference is we will know about a UK Govt contract and thus the sp will move up. This will not necessarily be the case if we are selling all we can make to UK businesses or overseas clients. Avacta will be under no obligation to share their weekly/monthly sales numbers with the market and therefore there would likely be no concrete news on which the MM’s can move the SP.
I was invested in NYCT and sales information was not released for months and the price wavered around the £3 mark. It wasn’t until they started landing publicly announced UK Govt contracts that the SP took off. We need the same to happen to AVCT. . . . in my humble opinion. GLA
US crying out for an effective LFD - Avacta Cavalry to the rescue?
https://www.propublica.org/article/rapid-testing-is-less-accurate-than-the-government-wants-to-admit/amp
Make that a drop to £1:02
Anyone know what caused that vertical drop in price to £1:05?
Article in today’s Spectator online edition:
“Assuming the vaccine does go on to be approved, how soon might it become available? Ben Osborn, Pfizer’s managing director in the UK, said in July that there were 40 million doses sitting in a Belgian warehouse ready to be sent to Britain. That would be enough to treat 20 million people, given that it requires two doses. But last week, Paul Duffy, vice-president of Pfizer Global Supply, said that there is ‘very minimal’ chance of the vaccine being distributed this year, even if it is approved this month. Distribution is more likely in the first half of next year, he said.
Correct me if I’m wrong but I believe that is the first time at a No 10 Press conference that Boris has referred to “lateral flow tests” that he then went on to say you could do yourself at home and get the result in 10 or 15 minutes. Excellent - let’s hope the press now start digging for who makes rapid turnaround lateral flow tests. It could be us
Does anyone say precisely when the tech transfer process began?
What element of the process is likely to be the most challenging and likely to be the cause of the delay?
I choose to put my faith in Dr AS and his stated and printed commitment to inform shareholders via an RNS as soon as the 10,000 batch has been validated.
Doubts over 'rapid turnaround' Covid tests pledged by Johnson
https://www.theguardian.com/world/2020/nov/02/doubts-over-rapid-turnaround-covid-tests-pledged-by-johnson?CMP=Share_iOSApp_Other
Wyndrum: that tattoo needs to read
“rof hsiw uoy tahw luferac eb” lol
Boris said and thanks to “Live Pause” I quote:
“We now have the immediate prospect of using many millions of cheap reliable and above all RAPID turn-around tests, tests that you can use yourself to tell you whether or not you’re infectious and get the result within 10 to 15 minutes and we know from trials across the country in schools and hospitals that we can use these tests not just to locate infectious people but to drive down the disease and so over the next few days and weeks we plan a steady but massive expansion in the deployment of these quick turnaround tests applying them in an ever growing number of situations from helping women to have their partners with them in labour wards when they’re giving birth to testing whole towns and even whole cities. The Army has been brought in to work on the logistics and the programme will begin in a matter of days. Working with local communities, local Government public health Directors, organisations of all kinds to help people discover whether or not they’re infectious and then immediately to get them to help them to self-isolate and stop the spread of the disease.”
Result in 10 to 15 minutes to tell if infectious
Good of Mr Brandon to overlook your spelling mistake; me, I'm not so kind - lol
Probably due to NDA’s imposed by UK Govt
I’ve read lots of messages over the past 24 hours about our CEO’s share sale to raise funds for his family’s next home. Personally I saw it as a positive as it was unlikely to be followed by bad news. However, many other posters here were quick to complain and I take issue with each and every one of them. To be fair, any feelings of “betrayal” should be directed at the market makers after all, it was the market makers who hailed the price down. The Moaning Minnies on here weren’t really morning about our CEO’s decision to fund his house purchase by selling some (3%) of his shares, they were moaning about the (temporary, less than 24hr) drop in the SP. Had the SP remained unaffected, I doubt many would have bothered to post. Instead, some “gamblers” allowed themselves to be duped by the MM’s and handed over their shares at a discount - actually I bought some of those yesterday so I guess I should thank our dear departed short term holders. Anyway, I’m off out now to my local newsagent to buy a “Good Luck In Your New Home” card for Dr Smith and his family. Might be nice if some of you genuine LTH followed suit? Have a good week-end.
Cruise ship operators will see this news as a God-send. Hopefully they will be getting travel correspondents “on board” with story and Avacta’s “Affimer” will get broader public exposure. Every little bit helps!
Just stepped in and topped up at £1:73 on HL. Didn’t think I’d be buying again as I have a significant 6-figure holding but this was just too good to miss. GLA LTH
Made in Chiii-naaah . . .